351 related articles for article (PubMed ID: 24362951)
1. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Beck JT; Hortobagyi GN; Campone M; Lebrun F; Deleu I; Rugo HS; Pistilli B; Masuda N; Hart L; Melichar B; Dakhil S; Geberth M; Nunzi M; Heng DY; Brechenmacher T; El-Hashimy M; Douma S; Ringeisen F; Piccart M
Breast Cancer Res Treat; 2014 Feb; 143(3):459-67. PubMed ID: 24362951
[TBL] [Abstract][Full Text] [Related]
2. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
[TBL] [Abstract][Full Text] [Related]
4. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Noguchi S; Masuda N; Iwata H; Mukai H; Horiguchi J; Puttawibul P; Srimuninnimit V; Tokuda Y; Kuroi K; Iwase H; Inaji H; Ohsumi S; Noh WC; Nakayama T; Ohno S; Rai Y; Park BW; Panneerselvam A; El-Hashimy M; Taran T; Sahmoud T; Ito Y
Breast Cancer; 2014 Nov; 21(6):703-14. PubMed ID: 23404211
[TBL] [Abstract][Full Text] [Related]
6. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Piccart M; Hortobagyi GN; Campone M; Pritchard KI; Lebrun F; Ito Y; Noguchi S; Perez A; Rugo HS; Deleu I; Burris HA; Provencher L; Neven P; Gnant M; Shtivelband M; Wu C; Fan J; Feng W; Taran T; Baselga J
Ann Oncol; 2014 Dec; 25(12):2357-2362. PubMed ID: 25231953
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Campone M; Beck JT; Gnant M; Neven P; Pritchard KI; Bachelot T; Provencher L; Rugo HS; Piccart M; Hortobagyi GN; Nunzi M; Heng DY; Baselga J; Komorowski A; Noguchi S; Horiguchi J; Bennett L; Ziemiecki R; Zhang J; Cahana A; Taran T; Sahmoud T; Burris HA
Curr Med Res Opin; 2013 Nov; 29(11):1463-73. PubMed ID: 23962028
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Burris HA; Lebrun F; Rugo HS; Beck JT; Piccart M; Neven P; Baselga J; Petrakova K; Hortobagyi GN; Komorowski A; Chouinard E; Young R; Gnant M; Pritchard KI; Bennett L; Ricci JF; Bauly H; Taran T; Sahmoud T; Noguchi S
Cancer; 2013 May; 119(10):1908-15. PubMed ID: 23504821
[TBL] [Abstract][Full Text] [Related]
9. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Yardley DA; Noguchi S; Pritchard KI; Burris HA; Baselga J; Gnant M; Hortobagyi GN; Campone M; Pistilli B; Piccart M; Melichar B; Petrakova K; Arena FP; Erdkamp F; Harb WA; Feng W; Cahana A; Taran T; Lebwohl D; Rugo HS
Adv Ther; 2013 Oct; 30(10):870-84. PubMed ID: 24158787
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Im YH; Karabulut B; Lee KS; Park BW; Adhav A; Cinkir HY; Abdel-Razeq H; Chang YC; Aksoy S; Im SA; Jeong J; Chae Y; Bowles J; Slimane K; Xue H; Kim SB
Breast Cancer Res Treat; 2021 Jul; 188(1):77-89. PubMed ID: 33728524
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
[TBL] [Abstract][Full Text] [Related]
12. Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
Decker T; Söling U; Hahn A; Maintz C; Kurbacher CM; Vehling-Kaiser U; Sent D; Klare P; Hagen V; Chiabudini M; Falkenstein J; Indorf M; Runkel E; Potthoff K
BMC Cancer; 2020 Apr; 20(1):286. PubMed ID: 32252684
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
[TBL] [Abstract][Full Text] [Related]
14. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Lüftner D; Schuetz F; Schneeweiss A; Hartkopf A; Bloch W; Decker T; Uleer C; Stötzer O; Foerster F; Schmidt M; Mundhenke C; Tesch H; Jackisch C; Fischer T; Kreuzeder J; Guderian G; Fasching PA
Int J Cancer; 2024 Jul; 155(1):128-138. PubMed ID: 38447007
[TBL] [Abstract][Full Text] [Related]
16. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
Rugo HS; Pritchard KI; Gnant M; Noguchi S; Piccart M; Hortobagyi G; Baselga J; Perez A; Geberth M; Csoszi T; Chouinard E; Srimuninnimit V; Puttawibul P; Eakle J; Feng W; Bauly H; El-Hashimy M; Taran T; Burris HA
Ann Oncol; 2014 Apr; 25(4):808-815. PubMed ID: 24615500
[TBL] [Abstract][Full Text] [Related]
17. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
[TBL] [Abstract][Full Text] [Related]
18. Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Ciccarese M; Fabi A; Moscetti L; Cazzaniga ME; Petrucelli L; Forcignanò R; Lupo LI; De Matteis E; Chiuri VE; Cairo G; Febbraro A; Giordano G; Giampaglia M; Bilancia D; La Verde N; Maiello E; Morritti M; Giotta F; Lorusso V; Latorre A; Scavelli C; Romito S; Cusmai A; Palmiotti G; Surico G
Breast Cancer Res Treat; 2017 Jun; 163(3):587-594. PubMed ID: 28353061
[TBL] [Abstract][Full Text] [Related]
19. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
[TBL] [Abstract][Full Text] [Related]
20. BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer.
Shao ZM; Cai L; Wang S; Hu X; Shen K; Wang H; Li H; Feng J; Liu Q; Cheng J; Wu X; Wang X; Li H; Luo T; Liu J; Amin K; Slimane K; Qiao Y; Liu Y; Tong Z
Discov Oncol; 2024 Jun; 15(1):237. PubMed ID: 38904918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]